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Background: Canine generalized demodicosis associated with hyperadrenocorticism is often problematic and
might be intractable. The aim of this study was to report the efficacy of a weekly application of spot-on
moxidectin/imidacloprid in dogs with hyperadrenocorticism and secondary generalized demodicosis.
Methods: Dogs with hyperadrenocorticism and secondary generalized demodicosis were included. The condition
of hyperadrenocorticism was treated and stabilized with trilostane before and throughout the study period in all
dogs.
Results: Average total live adult mite counts before treatment and after four, eight and 12 weeks of spot-on
moxidectin/imidacloprid (2.5/10 mg/kg) applications were 20.1 ± 6.3 (range, 13–33), 0.5 ± 0.7 (range, 0–2; 6/11
were negative), 0.2 ± 0.4 (range, 0–1; 9/11 were negative), 0.2 ± 0.4 (range, 0–1; 9/11 were negative) and 0.1 ± 0.3
(range, 0–1; 10/11 were negative) respectively; this difference was significant (P < 0.001). Ten of 11 dogs (90.1%)
achieved clinical remission, as demonstrated by the absence of demodectic mites at any life stage at monthly
scrapings for eight consecutive weeks, and maintained remission throughout the 12-month follow-up period.
Conclusion: The weekly application of spot-on moxidectin/imidacloprid appeared to be effective and safe against
generalized adult onset canine demodicosis associated with hyperadrenocorticism.
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Demodicosis is a relatively common canine skin disease
with localized and generalized (juvenile- and adult-onset)
forms [1]. Adult-onset canine generalized demodicosis is a
multifactorial disease with an etiology including genetic
factors and suppressed T-cell immunity [2]. Its develop-
ment is also associated with immunosuppressive treat-
ments, neoplasia and medical conditions characterized by
metabolic changes, such as hyperadrenocorticism, hypo-
thyroidism and diabetes mellitus [3].
Among evaluated therapeutic protocols for canine gene-
ralized demodicosis, oral ivermectin has been used most
widely worldwide. Milbemycin oxime, also a macrocyclic
lactone, has been commonly used in refractory cases [4].* Correspondence: hphuang@ntu.edu.tw
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distribution, and reproduction in any mediumThe efficacy of both of these antiparasitic agents is asso-
ciated with higher dosage and more frequent adminis-
tration [5-8]. A spot-on formulation of moxidectin, another
macrocyclic lactone, is licensed for the treatment of de-
modicosis in many countries [9] and has recently been reg-
istered in the authors’ country of practice.
Hyperadrenocorticism (HAC) is a common canine endo-
crine disorder characterized by chronically elevated circu-
lating concentrations of the steroid hormones produced by
the adrenal cortex [10]. Immunosuppression is a common
complication associated with long-term hyperadrenocor-
ticism, which renders dogs prone to the development of
secondary demodicosis and is often problematic and might
be intractable [3].
The purpose of this study was to evaluate the efficacy of
spot-on moxidectin/imidacloprid in dogs with hyperadre-
nocorticism and associated generalized demodicosis.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Case selection
Client-owned dogs with hyperadrenocorticism and sec-
ondary generalized demodicosis, initially not achieving
parasitic remission after oral ivermectin (Ivomec®; Merial
Limited, GA, USA; 0.5 mg/kg, once daily for at least five
weeks) in combination with trilostane (Vetoryl®; Dechra
Pharmaceuticals PLC, Stoke-on-Trent, UK), but had
reached maintained clinical and microscopic remission
with oral milbemycin oxime (Milbemycin A; Daiichi
Sankyo Co., Ltd., Japan; 0.5 mg/kg, once daily for at least
four weeks), but later relapsed after milbemycine oxime
discontinuation were included. Informed consent was
obtained from all dog owners prior to inclusion in the
study.
Diagnosis of generalized demodicosis
Generalized demodicosis was defined as demodicosis af-
fecting more than four small areas (<100 cm2) on the
body, at least one area > 100 cm2, or at least one paw.
Four skin scrapings, from four affected areas, were taken
in each dog exhibiting at least four lesional areas. The
diagnosis of demodicosis was based on the finding of
more than three live adult Demodex canis mites from at
least three of four scrapings, or from lesions > 100 cm2
or from a lesional paw [11].
Diagnosis and stabilization of hyperadrenocorticism
Diagnosis of hyperadrenocorticism had been based on
clinical signs (such as polydipsia, polyuria, polyphagia,
decreased activity level, panting, a pot-bellied appear-
ance, excessive hair loss or alopecia in general, chronic
pyoderma) and the results of routine serum biochemical
analyses (such as elevation of hepatic enzyme activities),
affirmative adrenocorticotropic hormone stimulation test
results and adrenal ultrasonographic images [12]. Stabi-
lized hyperadrenocorticism was defined as alleviation of
clinical signs (polydipsia and/or polyuria, activity level
and panting) and reduced excretion of post-ACTH corti-
sol within the therapeutic range (< 10 μg/dL) after four
weeks of trilostane treatment.
Treatment protocol of spot-on moxidectin/imidacloprid
A spot-on formulation of 10% imidacloprid and 2.5%
moxidectin (Advocate®, 0.1 ml/kg; Bayer HealthCare AG,
Leverkusen, Germany) was applied to each dog once
weekly for 12 weeks.
All dogs were evaluated every four weeks for 12 weeks:
four skin scrapings were taken from four initially affected
areas and routine blood tests were performed every four
weeks for 12 weeks. Side effects were recorded during the
study period.
In this study, the efficacy of spot-on moxidectin/
imidacloprid was defined as the absence of Demodex canismites in any life stage at monthly scrapings for eight con-
secutive weeks. These dogs received no other treatment
against ectoparasites during the study period.
Concomitant trilostane as the treatment for hyperadre-
nocorticism was carried on at unchanged dosage in all
dogs throughout the study period.
Follow up
After withdrawal of spot-on moxidectin/imidacloprid,
physical examination, routine blood tests and skin scrap-
ings were performed in all dogs at intervals four to eight
weeks over a period of 12 months. The dogs received no
treatment against ectoparasites during the period of follow
up for 12 months after discontinuation of moxidectin/
imidacloprid.
Statistical analyses
Total numbers of adult mites recovered from skin scrap-
ings taken before treatment and after four, eight and
12 weeks of treatment were compared by one-way ana-
lysis of variance (ANOVA). Parameters of routine blood
tests taken before treatment and after 12 weeks of treat-
ment were also compared by one-way ANOVA. The
Kolmogorov–Smirnov test was used to assess the nor-
mality of distribution of numeric and continuous data.
One-way ANOVA was used compare normally distrib-
uted variables between groups, and the Kruskal–Wallis
test was used to compare non-normally distributed vari-
ables. All statistical analyses were performed with the
SPSS software (version 13.0; SPSS Inc., Chicago, IL,
USA). Continuous data are presented as means ± stand-
ard deviations. Statistical significance was set at P ≤ 0.05.
Results
Eleven dogs fulfilled the inclusion criteria and were in-
cluded in this study (Table 1).
Effect of spot-on moxidectin/imidacloprid on clinical signs
Improvement generally became evident in 10 of 11 dogs
within four weeks after the start of treatment, with de-
creased severity of cutaneous inflammation of affected
areas. Clinical improvement was evident in all dogs
within eight weeks after the start of treatment, including
alleviation of inflammation and hair re-growth on the af-
fected areas/dorsal paws.
Effect of spot-on moxidectin/imidacloprid on live adult
mite counts
The average total live adult mite counts before treatment
and after four, eight and 12 weeks of spot-on
moxidectin/imidacloprid applications were 20.1 ± 6.3,
0.5 ± 0.7 (6/11 were negative), 0.2 ± 0.4 (9/11 were nega-
tive) and 0.1 ± 0.3 (10/11 were negative), respectively;
this difference was significant (P < 0.001; Table 2).
Table 1 Breed, sex age, body weight, duration of ivermectin therapy prior to and after concomitant trilostane,
duration of milbemycin oxime therapy, clinical signs associated with generalized demodicosis (GD) after withdrawal of
milbemycin oxime for eight weeks, clinical signs associated with hyperadrenocorticism (HAC) and trilostane dosage of
11 dogs








Clinical lesions associated with GD
after withdrawal of milbemycin
oxime (week of withdrawal)







Generalized erythema and pyoderma
mainly on both flanks (10)
Polydipsia, polyphagia, polyuria, decreased
activity, a potbellied appearance, muscular




12 y, FS Yorkshire
terrier (2.6 kg)
10/7 5
Generalized erythema and deep
pyoderma mainly on back (10)
Polydipsia, polyuria, decreased activity, a
potbellied appearance, muscular wasting,




12.5 y, FS Maltese
terrier (3.8 kg)
8/6 5
Generalized erythema and deep
pododermatitis mainly on face and
lateral thighs (8)
Polydipsia, polyphagia, polyuria, decreased
activity, panting, a potbellied appearance,
muscular wasting, generalized alopecia and
chronic pyoderma, calcinosis cutis;
2.3 mg/kg/day
4
11 y, FS Chihuahua
(1.8 kg)
9/6 7
Generalized erythema and deep
pododermatitis (Front two paws) (8)
Polydipsia, polyphagia, polyuria, decreased
activity, panting, a potbellied appearance,
muscular wasting, generalized alopecia and




13 y FS Maltese
terrier (5.1 kg)
6/6 7
Generalized erythema and pyoderma
and deep pododermatitis (four
paws) (8)
Polydipsia, polyphagia, polyuria, decreased
activity, panting, a potbellied appearance,
muscular wasting, generalized alopecia and
chronic pyoderma in general, concurrent
pyonephrosis (one kidney left);
2.3 mg/kg/day
6
10 y, M Shih Tzu
(6.1 kg)
8/6 5
Generalized erythema and pyoderma
and deep pododermatitis (four
paws) (9)
Polydipsia, polyuria, decreased activity,
panting, a potbellied appearance,




9 y, MC Shih Tzu
(8 kg)
8/6 5
Generalized erythema and deep
pododermatitis (front two paws) (8)
Polydipsia, polyphagia, polyuria, panting, a
potbellied appearance, muscular wasting,




13 y, MC Yorkshire
terrier (5 kg)
10/7 5
Generalized erythema and pyoderma
mainly on back (9)
Polydipsia, polyphagia, polyuria, decreased
activity, a potbellied appearance, muscular




11 y, FS Maltese
terrier (11.5 kg)
6/6 5
Generalized erythema and pyoderma
mainly on ventral chest (8)
Polydipsia, polyphagia, polyuria, decreased
activity, panting, a potbellied appearance,




12.5 y, FS Maltese
terrier (4.5 kg)
6/6 7
Generalized erythema and deep
pyoderma mainly on back (8)
Polydipsia, polyuria, decreased activity,
panting, a potbellied appearance, muscular
wasting, generalized alopecia, chronic
pyoderma and concurrent DM;
1.9 mg/kg/day
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Table 1 Breed, sex age, body weight, duration of ivermectin therapy prior to and after concomitant trilostane,
duration of milbemycin oxime therapy, clinical signs associated with generalized demodicosis (GD) after withdrawal of
milbemycin oxime for eight weeks, clinical signs associated with hyperadrenocorticism (HAC) and trilostane dosage of
11 dogs (Continued)
11





(two front paws) (8)
Polydipsia, polyuria, decreased activity,
panting, a potbellied appearance, muscular



















Period of non-mitidal treatment after
Milbemycin oxime withdrawn Mean:
8.5 weeks Median: 8 weeks
DM: diabetes mellitus, FS: spayed female, M: male, MC: castrated male, PD: polydipsia, PP: polyphagia, PU: polyuria, y: years.
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The owners of the dogs reported no side effects during
the treatment period. Among routine blood test parame-
ters, only pre- and post-treatment white blood cell
counts differed significantly (P < 0.001; Table 3).
Follow up
Ten of 11 dogs were free from clinical lesions associated
with generalized demodicosis and maintained microscopic
remission over 12 months after withdrawal of spot-on
moxidectin/imidacloprid. One dog never reached micro-
scopic remission after 12 months of follow-up and mul-
tiple skin scrapings revealed one to three live adult mites
throughout the period of following 12 months. Mild alo-
pecia and pyoderma on the dorsal paws remained. How-
ever the clinical improvement was appreciated by the
owner. The dogs received no other treatment againstTable 2 Mean number of Demodex mites in skin scrapings pr
moxidectin/imidacloprid (M/I)
No Case
Prior to trilostane Pre spot- on M/I
1 14 y, M, Pomeranian (2.8 kg) 17 15
2 12 y, FS Yorkshire terrier (2.6 kg) 26 28
3 12.5 y, FS Maltese terrier (3.8 kg) 20 18
4 11 y, FS Chihuahua (1.8 kg) 27 25
5 13 y FS Maltese terrier (5.1 kg) 30 33
6 10 y, M Shih Tzu (6.1 kg) 13 17
7 9 y, MC Shih Tzu (8 kg) 17 14
8 13 y, MC Yorkshire terrier (5 kg) 19 18
9 11 y, FS Maltese terrier (11.5 kg) 20 22
10 12.5 y, FS Maltese terrier (4.5 kg) 15 13
11 15 y, FS Shih Tzu (6.2 kg) 16 18ectoparasite during the period of follow up for 12 months
after discontinuation of moxidectin/imidacloprid.Discussion
The estimated efficacy of spot-on moxidectin/imidacloprid
treatment was 90.1% over the 12-month follow-up period,
which exceeded previously reports of 15–87% for spot-on
moxidectin/imidacloprid treatment of canine generalized
demodicosis [11,13]. The higher efficacy may be associ-
ated with the frequency of application, as in this study the
drug was administered once weekly, whereas in the previ-
ous reports a two- to four-week interval was used.
The high success rate of treatment might furthermore
be associated with the susceptibility of Demodex canis
mites to the new moxidectin/imidacloprid preparation,
which was introduced recently in our veterinary market.e-trilostane treatment, pre- and during spot-on
Total live adult mite count












Table 3 Results (± standard deviation, range) of routine blood tests performed before and after 12 weeks of treatment
with spot-on moxidectin/imidacloprid in 11 dogs with hyperadrenocorticism and generalized demodicosis
Parameter Reference range Before treatment After 12 weeks of treatment
Hemoglobin (g/dl) 11.5–18 15.2 ± 1.0 15.2 ± 1.0
(13.8–16.7) (13.7–16.7)
Packed cell volume (%) 35–52 42.7 ± 2.6 41.8 ± 3.0
(39–47) (38–48)
Red blood cells (× 106/μl) 5.2–7.5 6.1 ± 0.4 (5.5–6.9) 6.0 ± 0.5
(5.6–7.1)
White blood cells (/μl) 6000–15,500 14,718 ± 1549 11,963 ± 1601*
(12,400–17,600) (9700–14,200)
Albumin (g/dl) 2.6–3.7 2.9 ± 0.2 2.9 ± 0.2
(2.6–3.2) (2.6–3.1)
Alkaline phosphatase (U/l) 27–219 268.5 ± 194.8 244.5 ± 150.0
(90–752) (112–630)
Alanine aminotransferase (U/l) 20–123 98.6 ± 33.0 (67–170) 94.6 ± 22.2
(53–130)
Blood urea nitrogen (mg/dl) 7–27 24.0 ± 5.6 24.5 ± 5.4
(15–31) (16–32)
Creatinine (mg/dl) 0.5–1.5 1.4 ± 0.2 1.3 ± 0.2
(1.1–1.6) (1.0–1.7)
Glucose (mg/dl) 82–121 108.0 ± 8.3 108.2 ± 11.1
(97–119) (90–121)
Globulin (g/dl) 2.8–4.8 4.2 ± 0.3 4.1 ± 0.2
(3.8–4.6) (3.8–4.5)
*P < 0.05 vs. pretreatment.
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aration might explain a high susceptibility in the demo-
dectic mites. Together with a more frequent application, a
high susceptibility of Demodex mites to the new prepar-
ation likely can be the explanation of the short intervals
between treatment initiation and the first negative skin
scrapings (8 weeks in 9/11 dogs) and clinical remission
(12 weeks in 10/11 dogs).
The dogs in this study had been treated with other
macrocyclic lactones, ivermectin and milbemycin oxime,
prior to inclusion with remission achieved. Relapse of gen-
eralized demodicosis was presented after discontinuation
of milbemycin oxime treatment, prior to inclusion in the
study. In this study, the treatment-free period of milbe-
mycin oxim had though not been longer than approxi-
mately two months. Although the efficacy of macrocyclic
lactones may be variable in treating demodicosis, the
mechanism of macrocyclic lactones is similarly. The short
treatment-free period of milbemycin oxime might also
contribute to the fast resolution of the disease after initi-
ation of the moxidectin/imidacloprid treatment.
All dogs in our series had generalized demodicosis as-
sociated with hyperadrenocorticism, a metabolic disordercharacterized by multisystemic complications affecting
the cardiovascular, digestive (hepatic and pancreatic),
urogenital, muscular and/or cutaneous systems. Long-
term excessive cortisol concentrations may induce im-
munosuppression and predispose dogs to generalized
demodicosis [3,10]. In this study, 12 consecutive weekly
applications of spot-on moxidectin/imidacloprid were
well tolerated by these metabolism-compromised dogs,
with no reported side effect and no abnormality detec-
ted by routine blood tests.
Side effects of topical moxidectin, such as erythema
and scaling at the administration site are rarely reported
[14], but ataxia, lethargy, loss of appetite and vomiting
have been reported in dogs treated with oral moxidectin
[15]. The major adverse effects of systemic macrocyclic
lactones are neurotoxic, including lethargy, hypersali-
vation, ataxia, coma, mydriasis, clinical blindness and
seizure. Certain breeds of dogs (e.g., standard and mi-
niature Australian shepherds, border collies, collies,
German shepherds, longhaired whippets, Old English
and Shetland sheepdogs and silken windhounds) com-
monly display a mutation of the multiple drug resistance
gene (MDR1), which may cause defective P-glycoprotein
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lic lactones, including ivermectin and milbemycin,
through the accumulation of relatively high drug concen-
trations in the central nervous system, even when rela-
tively low doses are administered [16]. Adverse effects of
ivermectin are uncommon in other breeds and include
the neurotoxic effects listed above [5,6]. Milbemycin tox-
icity is rare and usually non-severe in dogs, including leth-
argy, vomiting, stupor, ataxia and trembling [8,17]. Thus,
milbemycin and spot-on moxidectin are alternative treat-
ments in dogs that are sensitive to ivermectin.
In our cases, clinical and microscopic remission had
been maintained with sustained milbemycin. Relapse of
demodicosis occurred when milbemycin was withdrawn.
A complete remission could possibly have been achieved
if milbemycin oxim treatment had been continued. Treat-
ment regimens including milbemycin are expensive and
often to be needed life-long. In terms of financial con-
cerns, spot-on moxidectin were more cost effective in
these dogs.
One dog (No. 5) in our series never reached micro-
scopic remission, but improved clinically. Although her
hyperadrenocorticism was stabilized throughout the
study period, her general condition was complicated by
chronic unilateral (left) pyonephrosis, which may have
resulted in the failure to achieve remission.
Higher concentration of ivermectin and milbemycin
seem to be associated with higher efficacy in the treat-
ment of canine generalized demodicosis [5-8]. Similarly,
the efficacy of weekly spot-on moxidectin/imidacloprid
applications in this study was higher than those of bi-
weekly or monthly regimens. Further evaluation of the
efficacy and toxicity of this treatment at higher doses or
shorter application intervals is warranted.
Our results demonstrate that the weekly application of
spot-on moxidectin/imidacloprid was effective in the
treatment of canine generalized demodicosis secondary
to hyperadrenocorticism. Twelve consecutive weekly ap-
plications of this treatment were well tolerated by these
metabolism-compromised dogs, with no side effect ob-
served and no abnormality detected by routine blood
tests.
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